Melanoma Dispatch
2.7K views | +0 today
Follow
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Myriad Genetics, Inc. - Myriad myPath(TM) Melanoma Test Improves the Reliability of Melanoma Diagnosis

"Myriad Genetics, Inc. (Nasdaq:MYGN) today presented results from a pivotal clinical validation study of the Myriad myPath™ Melanoma test at the 2014 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Ill. The Myriad myPath Melanoma test is a novel molecular test that accurately differentiates malignant melanoma from benign skin lesions with a high level of accuracy and helps physicians deliver a more objective and confident diagnosis for patients."

Cancer Commons's insight:

Myriad  |  Jun 2, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Blue Nevi Acquired in Older Men, Lacked Association with Melanoma

Blue Nevi Acquired in Older Men, Lacked Association with Melanoma | Melanoma Dispatch | Scoop.it

Blue nevi commonly occurred in older men and usually were not associated with melanoma, according to recent study results.


" 'Our findings support the concept that benign [blue nevi] are not uncommonly acquired in older age individuals and that they may be safely clinically followed in the absence of concerning clinical and/or dermoscopic features,' the researchers said."

Cancer Commons's insight:

Healio  |  May 7, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Rare Skin Cancer on Palms and Soles More Likely to Come Back Compared to Other Melanomas

Rare Skin Cancer on Palms and Soles More Likely to Come Back Compared to Other Melanomas | Melanoma Dispatch | Scoop.it

"A rare type of melanoma that disproportionately attacks the palms and soles and under the nails of Asians, African-Americans, and Hispanics, who all generally have darker skins, and is not caused by sun exposure, is almost twice as likely to recur than other similar types of skin cancer, according to results of a study in 244 patients.


"The finding about acral lentiginous melanoma, as the potentially deadly cancer is known, is part of a study to be presented May 31 by researchers at the Perlmutter Cancer Center of NYU Langone at the annual meeting of the American Society of Clinical Oncology in Chicago."

Cancer Commons's insight:

Medical Xpress  |  May 29, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

DNA Shed by Tumors Shows Promise for Non-Invasive Screening and Prognosis

DNA Shed by Tumors Shows Promise for Non-Invasive Screening and Prognosis | Melanoma Dispatch | Scoop.it

"Certain fragments of DNA shed by tumors into the bloodstream can potentially be used to non-invasively screen for early-stage cancers, monitor responses to treatment and help explain why some cancers are resistant to therapies, according to results of an international study led by Johns Hopkins Kimmel Cancer Center investigators.


"Analyzing blood samples from 640 patients with various cancers, the researchers used digital polymerase chain reaction-based technology (a sophisticated method of multiplying and measuring the number DNA molecules) to evaluate how well the DNA fragments predicted the presence of tumors in the patients."

Cancer Commons's insight:

Medical Xpress  |  Mar 6, 2014

more...
Cancer Commons's curator insight, March 6, 2014 2:39 PM

Medical Xpress  |  Mar 6, 2014

Cancer Commons's curator insight, March 6, 2014 2:39 PM

Medical Xpress  |  Mar 6, 2014